Latest Breaking News On - Danielle keatley - Page 1 : comparemela.com

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional American Depositary Shares - Structure Therapeutics (NASDAQ:GPCR)

SAN FRANCISCO, June 07, 2024 (GLOBE NEWSWIRE) Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and

New yorkUnited statesDanielle keatleyExchange commissionSyndicate departmentEquity syndicate prospectus departmentMorgan stanleyGoldman sachs coEquity syndicate departmentMorgan stanley coProspectus departmentStructure therapeutics incCapital markets corpGuggenheim securitiesStructure therapeuticsLeerink partners

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional American Depositary Shares

Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional American Depositary Shares
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesNew yorkDanielle keatleyDan budwickCapital markets corpMorgan stanley coEquity syndicate prospectus departmentSyndicate departmentGuggenheim securitiesMorgan stanleyStructure therapeutics incEquity syndicate departmentExchange commissionGoldman sachs coProspectus departmentTherapeutics announces closing

Structure Therapeutics Announces Pricing of Upsized $476 Million Public Offering

SAN FRANCISCO, June 05, 2024 Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary.

United statesNew yorkDan budwickDanielle keatleyEquity syndicate prospectus departmentMorgan stanley coSyndicate departmentEquity syndicate departmentStructure therapeutics incGuggenheim securitiesExchange commissionCapital markets corpMorgan stanleyProspectus departmentGoldman sachs coStructure therapeutics

Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study

GSBR-1290 was generally well-tolerated with no treatment-related serious adverse events over 12 weeks; 2.8% study discontinuation rate due to adverse events related to study drug in diabetes and 0%.

United statesDan budwickRaymond stevensDavid dalessioDanielle keatleyCompany annual report on formDuke universityDivision of endocrinologyExchange commissionStructure therapeutics incCompany phaseDavidd alessioTolerability resultsTreatment emergent adverse eventsObesity cohortMixed model

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Danielle keatleyDan budwickRaymond stevensStructure therapeutics incExchange commissionCompany annual report on formTherapeutics reports third quarterPrivate securities litigation reform actAnnual reportQuarterly reportConsolidated statements